Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
21 studies found for:    anti-GD2 monoclonal antibody
Show Display Options
Rank Status Study
1 Active, not recruiting Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma
Condition: Neuroblastoma
Interventions: Biological: beta-glucan;   Biological: monoclonal antibody 3F8;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
2 Completed Beta-Glucan and Monoclonal Antibody in Treating Patients With Metastatic Neuroblastoma
Condition: Neuroblastoma
Interventions: Biological: beta-glucan;   Biological: monoclonal antibody 3F8
3 Completed Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma
Conditions: Disseminated Neuroblastoma;   Recurrent Neuroblastoma;   Regional Neuroblastoma
Interventions: Biological: monoclonal antibody Ch14.18;   Drug: isotretinoin;   Biological: aldesleukin;   Biological: sargramostim
4 Not yet recruiting Phase I Study of Investigational Medicinal Products in Children With Relapsed/Refractory Neuroblastoma
Condition: Neuroblastoma
Interventions: Drug: Nivolumab;   Drug: Ch14.18/CHO
5 Completed ch14.18/CHO Bridging Study
Condition: Neuroblastoma
Intervention: Drug: ch14.18/CHO
6 Unknown  Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)
Condition: Neuroblastoma
Interventions: Drug: ch14.18/CHO;   Drug: Aldesleukin;   Drug: Isotretinoin
7 Recruiting Therapy for Children With Advanced Stage Neuroblastoma
Condition: Neuroblastoma
Interventions: Drug: cyclophosphamide;   Drug: topotecan;   Biological: hu14.18K322A;   Procedure: peripheral blood stem cell harvest;   Procedure: surgical resection;   Drug: cisplatin;   Drug: etoposide;   Drug: doxorubicin;   Drug: vincristine;   Drug: busulfan;   Drug: melphalan;   Biological: peripheral blood stem cell transplantation;   Biological: natural killer cell infusion;   Radiation: radiation therapy;   Biological: GM-CSF;   Biological: G-CSF;   Drug: mesna;   Drug: levetiracetam;   Biological: interleukin-2;   Drug: Isotretinoin
8 Recruiting Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma
Condition: Neuroblastoma
Interventions: Biological: Anti-GD2 3F8 Monoclonal Antibody;   Drug: GM-CSF (granulocyte-macrophage colony-stimulating factor);   Drug: oral isotretinoin
9 Active, not recruiting Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma
Condition: Neuroblastoma
Intervention: Biological: anti-GD2 murine IgG3 monoclonal antibody 3F8
10 Active, not recruiting Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma
Condition: Neuroblastoma
Interventions: Biological: Humanized anti-GD2 antibody;   Drug: Chemotherapy;   Other: Cytokines;   Biological: Natural killer cells
11 Recruiting Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma
Condition: Recurrent Osteosarcoma
Interventions: Biological: humanized anti-GD2 antibody;   Drug: GM-CSF
12 Completed Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment
Condition: Neuroblastoma
Interventions: Biological: beta-glucan;   Biological: monoclonal antibody 3F8;   Biological: sargramostim;   Drug: isotretinoin
13 Recruiting Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma
Conditions: Recurrent Neuroblastoma;   Stage 4 Neuroblastoma
Interventions: Biological: Dinutuximab;   Drug: Isotretinoin;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Other: Pharmacological Study
14 Completed Pharmacokinetics of Ch14.18 in Younger Patients With High-Risk Neuroblastoma
Conditions: Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Neurotoxicity Syndrome;   Pain;   Regional Neuroblastoma;   Stage 4 Neuroblastoma;   Stage 4S Neuroblastoma
Interventions: Other: Cytology Specimen Collection Procedure;   Other: Pharmacological Study
15 Recruiting Pretreatment Anti-Therapeutic Antibodies (PATA) in Patients Treated With hu14.18K322A Antibody
Conditions: Ewing Family of Tumors;   Melanoma;   Neuroblastoma;   Osteosarcoma
16 Recruiting NB2013-HR German (GPOH) / Dutch (DCOG) Trial
Condition: Neuroblastoma
Interventions: Drug: antibody ch14.18;   Drug: GM-CSF;   Drug: IL-2 i.v.;   Drug: IL-2 s.c.;   Drug: Retinoic acid
17 Active, not recruiting 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow
Condition: Neuroblastoma
Intervention: Biological: 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic
18 Active, not recruiting A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma
Conditions: Neuroblastoma;   Melanoma;   Osteosarcoma;   Ewing Sarcoma
Intervention: Biological: Anti-GD2 antibody
19 Unknown  CH14.18 1021 Antibody and IL2 After Haplo SCT in Children With Relapsed Neuroblastoma
Condition: Neuroblastoma Recurrent
Intervention: Drug: ch14.18/CHO
20 Recruiting High Risk Neuroblastoma Study 1.7 of SIOP-Europe (SIOPEN)
Condition: Neuroblastoma
Interventions: Drug: Vincristine;   Drug: Aldesleukin;   Drug: ch14.18/CHO;   Drug: Carboplatin;   Drug: Etoposide;   Drug: Cisplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: G-CSF;   Drug: Busulfan;   Drug: Melphalan

   Previous Page Studies Shown (1-20) Next Page (21-21) Show next page of results    Last Page
Indicates status has not been verified in more than two years